Key result
High concentrations of levosimendan inhibited in-vitro platelet aggregation, but clinically relevant doses had no significant effect.
Why the study?
Does levosimendan inhibit platelet aggregation in vitro?
Does levosimendan inhibit platelet aggregation in vitro?
Levosimendan does not significantly inhibit platelet aggregation at clinically relevant doses in vitro.
Answers are grounded in this paper and cite their sources.
No platelet inhibition at clinically relevant levosimendan doses in vitro; leaves open in vivo antithrombotic relevance.
OBJECTIVE: Levosimendan enhances cardiac contractility by increasing myocyte sensitivity to calcium and causing vasodilatation. Although studies have evaluated the efficacy of levosimendan in heart failure, whether levosimendan produces an effect on platelets is a subject of controversy. In the present study, the in-vitro effect of levosimendan on platelet aggregation was investigated. The effect of levosimendan on the cyclic AMP concentration was determined according to its second mode of action as a selective phosphodiesterase III inhibitor. MATERIALS AND METHODS: Platelet aggregation setting was performed using venous blood from three healthy volunteers. Different concentrations of levosimendan solution were prepared that would result in 0.04-125 µg/ml levosimendan concentrations in whole blood and in platelet-enriched plasma. After incubation for 3 min at 37°C, aggregation responses were evaluated with ADP (10 µmol/l), collagen (5 µg/ml), or NaCl. The cyclic AMP concentration was determined using the enzyme-linked immunosorbent assay technique. RESULTS: The in-vitro results clearly showed that there was only a relationship between a high levosimendan concentration (12-125 µg/ml) and inhibition of platelet aggregation that was negatively dependent on the cAMP concentration. CONCLUSION: Levosimendan has no significant effect as a phosphodiesterase III inhibitor on in-vitro platelet aggregation in clinically relevant doses.
No takes yet. Share an insight, caveat, or question.
Plaschke et al. (2012) studied Healthy (n=3). Levosimendan was evaluated on Platelet aggregation and cyclic AMP concentration. High concentrations of levosimendan inhibited in-vitro platelet aggregation, but clinically relevant doses had no significant effect.
Synapse has enriched 10 related papers. Consider them for comparative context: